| Year |
Citation |
Score |
| 2024 |
Neal J, Pavlakis N, Kim SW, Goto Y, Lim SM, Mountzios G, Fountzilas E, Mochalova A, Christoph DC, Bearz A, Quantin X, Palmero R, Antic V, Chun E, Edubilli TR, et al. CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2302166. PMID 38552197 DOI: 10.1200/JCO.23.02166 |
0.32 |
|
| 2024 |
Waliany S, Neal JW, Engel-Nitz N, Lam C, Lin F, Park L, Le L, Nagasaka M. HER2-Mutant Advanced and/or Metastatic Non-Small-Cell Lung Cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes. Clinical Lung Cancer. PMID 38403548 DOI: 10.1016/j.cllc.2024.01.002 |
0.399 |
|
| 2024 |
Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, et al. Consolidation Osimertinib versus Durvalumab versus Observation following Concurrent Chemoradiation in Unresectable EGFR-Mutant Non-Small-Cell Lung Cancer: A Multicenter Retrospective Cohort Study. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 38278303 DOI: 10.1016/j.jtho.2024.01.012 |
0.391 |
|
| 2023 |
Franquiz MJ, Waliany S, Xu AY, Hnatiuk A, Wu SM, Cheng P, Wakelee HA, Neal J, Witteles R, Zhu H. Osimertinib-Associated Cardiomyopathy In Patients With Non-Small Cell Lung Cancer: A Case Series. Jacc. Cardiooncology. 5: 839-841. PMID 38205011 DOI: 10.1016/j.jaccao.2023.07.006 |
0.369 |
|
| 2023 |
Ou SI, Prawitz T, Lin HM, Hong JL, Tan M, Proskorovsky I, Hernandez L, Jin S, Zhang P, Lin J, Patel J, Nguyen D, Neal JW. Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison. Clinical Lung Cancer. PMID 38114357 DOI: 10.1016/j.cllc.2023.11.011 |
0.446 |
|
| 2023 |
Karacosta LG, Pancirer D, Preiss JS, Benson JA, Trope W, Shrager JB, Sung AW, Neal JW, Bendall SC, Wakelee H, Plevritis SK. Phenotyping EMT and MET cellular states in lung cancer patient liquid biopsies at a personalized level using mass cytometry. Scientific Reports. 13: 21781. PMID 38065965 DOI: 10.1038/s41598-023-46458-5 |
0.305 |
|
| 2023 |
Hui C, Brown E, Wong S, Das M, Wakelee H, Neal J, Ramchandran K, Myall NJ, Pham D, Xing L, Yang Y, Kovalchuk N, Yuan Y, Lu Y, Xiang M, et al. Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial. Clinical Lung Cancer. PMID 38040540 DOI: 10.1016/j.cllc.2023.11.004 |
0.31 |
|
| 2023 |
Choi E, Su CC, Wu JT, Aredo JV, Neal JW, Leung AN, Backhus LM, Lui NS, Le Marchand L, Stram DO, Liang SY, Cheng I, Wakelee HA, Han SS. Second Primary Lung Cancer Among Lung Cancer Survivors Who Never Smoked. Jama Network Open. 6: e2343278. PMID 37966839 DOI: 10.1001/jamanetworkopen.2023.43278 |
0.325 |
|
| 2023 |
Choi E, Luo SJ, Ding VY, Wu JT, Kumar AV, Wampfler J, Tammemägi MC, Wilkens LR, Aredo JV, Backhus LM, Neal JW, Leung AN, Freedman ND, Hung RJ, Amos CI, et al. Risk model-based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model. Cancer. PMID 37877788 DOI: 10.1002/cncr.35069 |
0.305 |
|
| 2023 |
Su CC, Wu JT, Choi E, Myall NJ, Neal JW, Kurian AW, Stehr H, Wood D, Henry SM, Backhus LM, Leung AN, Wakelee HA, Han SS. Overall Survival Among Patients With De Novo Stage IV Metastatic and Distant Metastatic Recurrent Non-Small Cell Lung Cancer. Jama Network Open. 6: e2335813. PMID 37751203 DOI: 10.1001/jamanetworkopen.2023.35813 |
0.379 |
|
| 2023 |
Wolf J, Souquet PJ, Goto K, Cortot A, Baik C, Heist R, Kim TM, Han JY, Neal JW, Mansfield AS, Gilloteau I, Nwana N, Waldron-Lynch M, Davis KL, Giovannini M, et al. Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review. Clinical Lung Cancer. PMID 37741716 DOI: 10.1016/j.cllc.2023.08.011 |
0.349 |
|
| 2023 |
Vaidya R, Unger JM, Qian L, Minichiello K, Herbst RS, Gandara DR, Neal JW, Leal TA, Patel JD, Dragnev KH, Waqar SN, Edelman MJ, Sigal EV, Adam SJ, Malik S, et al. Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP). Jco Precision Oncology. 7: e2300218. PMID 37677122 DOI: 10.1200/PO.23.00218 |
0.361 |
|
| 2023 |
Patel SR, Neal JW. Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer? Translational Lung Cancer Research. 12: 1631-1635. PMID 37577327 DOI: 10.21037/tlcr-23-273 |
0.407 |
|
| 2023 |
Bodor JN, Patel JD, Wakelee HA, Levy BP, Borghaei H, Pellini B, Costello MR, Dowell JE, Finley G, Huang CH, Neal JW, Nieva JJ, Puri S, Socinski MA, Thomas C, et al. Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked. Clinical Lung Cancer. PMID 37451930 DOI: 10.1016/j.cllc.2023.05.003 |
0.381 |
|
| 2023 |
Saad MB, Hong L, Aminu M, Vokes NI, Chen P, Salehjahromi M, Qin K, Sujit SJ, Lu X, Young E, Al-Tashi Q, Qureshi R, Wu CC, Carter BW, Lin SH, ... ... Neal JW, et al. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study. The Lancet. Digital Health. PMID 37268451 DOI: 10.1016/S2589-7500(23)00082-1 |
0.309 |
|
| 2023 |
Ou SI, Lin HM, Hong JL, Yin Y, Jin S, Lin J, Mehta M, Zhang P, Nguyen D, Neal JW. Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison. Lung Cancer (Amsterdam, Netherlands). 179: 107186. PMID 37075617 DOI: 10.1016/j.lungcan.2023.107186 |
0.304 |
|
| 2023 |
Alhusaini S, Lanman TA, Ko RB, Therkelsen KE, Eyben RV, Diehn M, Soltys SG, Pollom EL, Chin A, Vitzthum L, Wakelee HA, Padda SK, Ramchandran K, Loo BW, Neal JW, et al. Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI staging. Frontiers in Oncology. 13: 1139940. PMID 37035171 DOI: 10.3389/fonc.2023.1139940 |
0.325 |
|
| 2023 |
Grant MJ, Aredo JV, Starrett JH, Stockhammer P, van Alderwerelt van Rosenburgh IK, Wurtz A, Piper-Valillo AJ, Piotrowska Z, Falcon C, Yu HA, Aggarwal C, Scholes D, Patil T, Nguyen C, Phadke M, ... ... Neal J, et al. Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36913537 DOI: 10.1158/1078-0432.CCR-22-3497 |
0.384 |
|
| 2022 |
Aredo JV, Wakelee HA, Hui AB, Padda SK, Joshi ND, Guo HH, Chaudhuri A, Diehn M, Loo BW, Neal JW. Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer. Cancer Treatment and Research Communications. 33: 100659. PMID 36427429 DOI: 10.1016/j.ctarc.2022.100659 |
0.385 |
|
| 2022 |
Hui C, Qu V, Wang JY, von Eyben R, Chang YC, Chiang PL, Liang CH, Lu JT, Li G, Hayden-Gephart M, Wakelee H, Neal J, Ramchandran K, Das M, Nagpal S, et al. Local control of brain metastases with osimertinib alone in patients with EGFR-mutant non-small cell lung cancer. Journal of Neuro-Oncology. PMID 36227422 DOI: 10.1007/s11060-022-04145-x |
0.368 |
|
| 2022 |
Chu T, Zhang W, Zhang B, Zhong R, Zhang X, Gu A, Shi C, Wang H, Xiong L, Lu J, Qian J, Zhang Y, Dong Y, Teng J, Gao Z, ... ... Neal JW, et al. Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study. Translational Lung Cancer Research. 11: 1394-1404. PMID 35958322 DOI: 10.21037/tlcr-22-438 |
0.402 |
|
| 2022 |
Devine M, Merriott DJ, No HJ, Lau B, Say C, Yoo C, Yi E, Ko RB, Neal JW, Wakelee HA, Das M, Loo BW, Diehn M, Chin AL, Vitzthum LK. Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer. Practical Radiation Oncology. PMID 35858658 DOI: 10.1016/j.prro.2022.06.013 |
0.359 |
|
| 2022 |
Lu D, Ma Z, Huang D, Zhang J, Li J, Zhi P, Zhang L, Feng Y, Ge X, Zhai J, Jiang M, Zhou X, Simone CB, Neal JW, Patel SR, et al. Clinicopathological characteristics and prognostic significance of HDAC11 protein expression in non-small cell lung cancer: a retrospective study. Translational Lung Cancer Research. 11: 1119-1131. PMID 35832445 DOI: 10.21037/tlcr-22-403 |
0.389 |
|
| 2022 |
Waliany S, Wakelee H, Ramchandran K, Das M, Huang J, Myall N, Li C, Pagtama J, Tisch AH, Neal JW. Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens. Clinical Lung Cancer. PMID 35753988 DOI: 10.1016/j.cllc.2022.05.015 |
0.346 |
|
| 2022 |
No HJ, Raja N, Von Eyben R, Das M, Roy M, Myall N, Neal J, Wakelee H, Chin A, Diehn M, Loo BW, Chang DT, Pollom EL, Vitzthum LK. Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms. International Journal of Radiation Oncology, Biology, Physics. PMID 35654305 DOI: 10.1016/j.ijrobp.2022.04.050 |
0.367 |
|
| 2022 |
Govindan R, Aggarwal C, Antonia SJ, Davies M, Dubinett SM, Ferris A, Forde PM, Garon EB, Goldberg SB, Hassan R, Hellmann MD, Hirsch FR, Johnson ML, Malik S, Morgensztern D, ... Neal JW, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. Journal For Immunotherapy of Cancer. 10. PMID 35640927 DOI: 10.1136/jitc-2021-003956 |
0.386 |
|
| 2022 |
Shah MP, Neal JW. Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer. Drugs. PMID 35412115 DOI: 10.1007/s40265-022-01698-z |
0.366 |
|
| 2022 |
Remon J, Lacas B, Herbst R, Reck M, Garon EB, Scagliotti GV, Ramlau R, Hanna N, Vansteenkiste J, Yoh K, Groen HJM, Heymach JV, Mandrekar SJ, Okamoto I, Neal JW, et al. ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. European Journal of Cancer (Oxford, England : 1990). 166: 112-125. PMID 35286903 DOI: 10.1016/j.ejca.2022.02.002 |
0.382 |
|
| 2022 |
Chao Y, Zhou J, Hsu S, Ding N, Li J, Zhang Y, Xu X, Tang X, Wei T, Zhu Z, Chu Q, Neal JW, Wu JT, Song Y, Hu J. Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer. Translational Lung Cancer Research. 11: 295-306. PMID 35280322 DOI: 10.21037/tlcr-22-72 |
0.372 |
|
| 2022 |
Goldman JW, Karlovich C, Sequist LV, Melnikova V, Franovic A, Gadgeel SM, Reckamp KL, Camidge DR, Pérol M, Ou SI, Liu SV, Yu HA, Soria JC, Socinski MA, Mekhail TM, ... ... Neal JW, et al. Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an Tyrosine Kinase Inhibitor. Jco Precision Oncology. 2: 1-13. PMID 35135111 DOI: 10.1200/PO.17.00116 |
0.378 |
|
| 2021 |
Padda SK, Aredo JV, Vali S, Singh NK, Vasista SM, Kumar A, Neal JW, Abbasi T, Wakelee HA. Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of -Mutated Non-Small-Cell Lung Cancer. Jco Precision Oncology. 5: 153-162. PMID 34994595 DOI: 10.1200/PO.20.00172 |
0.317 |
|
| 2021 |
Aredo JV, Wakelee HA, Neal JW, Padda SK. Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer. Cancer Treatment and Research Communications. 30: 100497. PMID 34920242 DOI: 10.1016/j.ctarc.2021.100497 |
0.397 |
|
| 2021 |
Choi E, Luo SJ, Aredo JV, Backhus LM, Wilkens LR, Su CC, Neal JW, Le Marchand L, Cheng I, Wakelee HA, Han SS. The Survival Impact of Second Primary Lung Cancer in Patients with Lung Cancer. Journal of the National Cancer Institute. PMID 34893871 DOI: 10.1093/jnci/djab224 |
0.347 |
|
| 2021 |
White MN, Piper-Vallillo AJ, Gardner RM, Cunanan K, Neal JW, Das M, Padda SK, Ramchandran K, Chen TT, Sequist LV, Piotrowska Z, Wakelee HA. Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib. Clinical Lung Cancer. PMID 34887193 DOI: 10.1016/j.cllc.2021.11.001 |
0.381 |
|
| 2021 |
Hellyer JA, White MN, Gardner RM, Cunanan K, Padda SK, Das M, Ramchandran K, Neal JW, Wakelee HA. Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer. Clinical Lung Cancer. PMID 34838441 DOI: 10.1016/j.cllc.2021.09.004 |
0.432 |
|
| 2021 |
Aredo JV, Hellyer JA, Neal JW, Wakelee HA. Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 16: 1994-1998. PMID 34809803 DOI: 10.1016/j.jtho.2021.07.033 |
0.304 |
|
| 2021 |
Padda SK, Reckamp KL, Koczywas M, Neal JW, Kawashima J, Kong S, Huang DB, Kowalski M, Wakelee HA. A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. PMID 34773474 DOI: 10.1007/s00280-021-04369-0 |
0.41 |
|
| 2021 |
Devine M, Merriott DJ, Say C, Yoo C, Yi E, Lau B, Ko RB, Shaheen S, Neal JW, Wakelee HA, Das M, Loo BW, Diehn M, Chin AL, Vitzthum L. Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics. 111: e435. PMID 34701446 DOI: 10.1016/j.ijrobp.2021.07.1235 |
0.32 |
|
| 2021 |
Ellis-Caleo T, Neal JW. The role of ramucirumab with docetaxel in epidermal growth factor receptor mutant and wild-type non-small cell lung cancer. Journal of Thoracic Disease. 13: 4864-4871. PMID 34527325 DOI: 10.21037/jtd-21-557 |
0.359 |
|
| 2021 |
Waliany S, Zhu H, Wakelee H, Padda SK, Das M, Ramchandran K, Myall NJ, Chen T, Witteles RM, Neal JW. Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 34418561 DOI: 10.1016/j.jtho.2021.07.030 |
0.309 |
|
| 2021 |
Shah MP, Aredo JV, Padda SK, Ramchandran KJ, Wakelee HA, Das MS, Neal JW. EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy. Clinical Lung Cancer. PMID 34391686 DOI: 10.1016/j.cllc.2021.07.001 |
0.393 |
|
| 2021 |
Neal JW, Costa DB, Muzikansky A, Shrager JB, Lanuti M, Huang J, Ramachandran KJ, Rangachari D, Huberman MS, Piotrowska Z, Kris MG, Azzoli CG, Sequist LV, Chaft JE. Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III -Mutant Non-Small-Cell Lung Cancer. Jco Precision Oncology. 5: 325-332. PMID 34151132 DOI: 10.1200/PO.20.00301 |
0.388 |
|
| 2021 |
Riely GJ, Neal JW, Camidge DR, Spira AI, Piotrowska Z, Costa DB, Tsao AS, Patel JD, Gadgeel SM, Bazhenova L, Zhu VW, West HL, Mekhail T, Gentzler RD, Nguyen D, et al. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial. Cancer Discovery. PMID 33632775 DOI: 10.1158/2159-8290.CD-20-1598 |
0.38 |
|
| 2021 |
White MN, Piotrowska Z, Stirling K, Liu SV, Banwait MK, Cunanan K, Sequist LV, Wakelee HA, Hausrath D, Neal JW. Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression. Clinical Lung Cancer. PMID 33610453 DOI: 10.1016/j.cllc.2021.01.010 |
0.419 |
|
| 2021 |
Aredo JV, Mambetsariev I, Hellyer JA, Amini A, Neal JW, Padda SK, McCoach CE, Riess JW, Cabebe EC, Naidoo J, Abuali T, Salgia R, Loo BW, Diehn M, Han SS, et al. Durvalumab for Stage III EGFR-Mutated Non-Small Cell Lung Cancer After Definitive Chemoradiotherapy. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 33588109 DOI: 10.1016/j.jtho.2021.01.1628 |
0.434 |
|
| 2021 |
Hellyer JA, Aredo JV, Das M, Ramchandran K, Padda SK, Neal JW, Wakelee HA. Brief Report: Role of Consolidation Durvalumab in patients with EGFR and HER2 Mutant Unresectable Stage III NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 33539970 DOI: 10.1016/j.jtho.2020.12.020 |
0.402 |
|
| 2021 |
Zhang M, Rodrigues AJ, Pollom EL, Gibbs IC, Soltys SG, Hancock SL, Neal JW, Padda SK, Ramchandran KJ, Wakelee HA, Chang SD, Lim M, Hayden Gephart M, Li G. Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases. Journal of Neuro-Oncology. PMID 33415659 DOI: 10.1007/s11060-020-03686-3 |
0.35 |
|
| 2021 |
Ou SI, Lin HM, Hong J, Yin Y, Jin S, Lin J, Mehta M, Nguyen D, Neal JW. Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations. Journal of Clinical Oncology. 39: 9098-9098. DOI: 10.1200/JCO.2021.39.15_SUPPL.9098 |
0.313 |
|
| 2021 |
White M, Neal J, Gardner R, Cunanan K, Das M, Padda S, Ramchandran K, Chen T, Wakelee H. 141P Chemotherapy with or without immunotherapy or bevacizumab for EGFR-mutated lung cancer after progression on osimertinib Journal of Thoracic Oncology. 16: S773-S774. DOI: 10.1016/S1556-0864(21)01983-3 |
0.398 |
|
| 2021 |
Spira A, Ramalingam S, Neal J, Piotrowska Z, Mekhail T, Tsao A, Gentzler R, Riely G, Bazhenova L, Gadgeel S, Nguyen D, Johnson M, Vincent S, Jin S, Griffin C, et al. OA15.01 Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy Journal of Thoracic Oncology. 16: S873-S874. DOI: 10.1016/j.jtho.2021.08.082 |
0.321 |
|
| 2021 |
Remon J, Lacas B, Herbst R, Reck M, Garon E, Scagliotti G, Ramlau R, Hanna N, Vansteenkiste J, Yoh K, Groen H, Heymach J, Mandrekar S, Okamoto I, Neal J, et al. P01.21 ANSELMA: Antiangiogenic Second Line Lung Cancer Meta-Analysis on Individual Patient Data in Non-Small Cell Lung Cancer, Again Relevant in ICI Era Journal of Thoracic Oncology. 16: S244-S245. DOI: 10.1016/J.JTHO.2021.01.345 |
0.374 |
|
| 2021 |
Aredo J, Wakelee H, Neal J, Padda S. P76.70 Afatinib After Progression on Osimertinib in Patients with EGFR-Mutated Lung Adenocarcinoma Journal of Thoracic Oncology. 16: S619. DOI: 10.1016/J.JTHO.2021.01.1127 |
0.358 |
|
| 2021 |
Aredo J, Hellyer J, Neal J, Padda S, McCoach C, Riess J, Cabebe E, Loo B, Diehn M, Wakelee H. MO01.01 Durvalumab for Patients with Stage III EGFR-Mutated Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy Journal of Thoracic Oncology. 16: S15. DOI: 10.1016/J.JTHO.2020.10.049 |
0.423 |
|
| 2020 |
Shah MP, Neal JW. Relative Impact of Anticancer Therapy on Unplanned Hospital Care in Patients With Non-Small-Cell Lung Cancer. Jco Oncology Practice. OP2000612. PMID 33351677 DOI: 10.1200/OP.20.00612 |
0.33 |
|
| 2020 |
Park M, Ho DY, Wakelee HA, Neal JW. Opportunistic Invasive Fungal Infections Mimicking Progression of Non-Small-Cell Lung Cancer. Clinical Lung Cancer. PMID 33168426 DOI: 10.1016/j.cllc.2020.10.001 |
0.34 |
|
| 2020 |
Binkley MS, Jeon YJ, Nesselbush M, Moding EJ, Nabet BY, Almanza D, Kunder C, Stehr H, Yoo CH, Rhee S, Xiang M, Chabon JJ, Hamilton E, Kurtz DM, Gojenola L, ... ... Neal JW, et al. KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibition. Cancer Discovery. PMID 33071215 DOI: 10.1158/2159-8290.CD-20-0282 |
0.322 |
|
| 2020 |
Nabet BY, Esfahani MS, Moding EJ, Hamilton EG, Chabon JJ, Rizvi H, Steen CB, Chaudhuri AA, Liu CL, Hui AB, Almanza D, Stehr H, Gojenola L, Bonilla RF, Jin MC, ... ... Neal JW, et al. Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell. PMID 33007267 DOI: 10.1016/j.cell.2020.09.001 |
0.309 |
|
| 2020 |
Waliany S, Lee D, Witteles RM, Neal JW, Nguyen P, Davis MM, Salem JE, Wu SM, Moslehi JJ, Zhu H. Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure. Annual Review of Pharmacology and Toxicology. PMID 32776859 DOI: 10.1146/Annurev-Pharmtox-010919-023451 |
0.333 |
|
| 2020 |
Zhou M, Joshi N, Raj KP, Wakelee H, Neal JW. PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review. Clinical Lung Cancer. PMID 32624413 DOI: 10.1016/J.Cllc.2020.05.012 |
0.33 |
|
| 2020 |
Riess JW, Jahchan NS, Das M, Zach Koontz M, Kunz PL, Wakelee HA, Schatzberg A, Sage J, Neal JW. A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS. Cancer Treatment and Research Communications. 23: 100174. PMID 32413603 DOI: 10.1016/J.Ctarc.2020.100174 |
0.459 |
|
| 2020 |
Chabon JJ, Hamilton EG, Kurtz DM, Esfahani MS, Moding EJ, Stehr H, Schroers-Martin J, Nabet BY, Chen B, Chaudhuri AA, Liu CL, Hui AB, Jin MC, Azad TD, Almanza D, ... ... Neal JW, et al. Integrating genomic features for non-invasive early lung cancer detection. Nature. 580: 245-251. PMID 32269342 DOI: 10.1038/S41586-020-2140-0 |
0.462 |
|
| 2020 |
Hellmann MD, Nabet BY, Rizvi H, Chaudhuri AA, Wells DK, Dunphy MP, Chabon JJ, Liu CL, Hui AB, Arbour KC, Luo J, Preeshagul IR, Moding EJ, Almanza D, Bonilla RF, ... ... Neal JW, et al. Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32046999 DOI: 10.1158/1078-0432.Ccr-19-3418 |
0.363 |
|
| 2020 |
Skoulidis F, Neal JW, Akerley WL, Paik PK, Papagiannakopoulos T, Reckamp KL, Riess JW, Jenkins Y, Holland S, Parlati F, Shen Y, Whiting SH, Rizvi NA. A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNSCLC). Journal of Clinical Oncology. 38: TPS9627-TPS9627. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps9627 |
0.463 |
|
| 2020 |
Neal JW, Lim FL, Felip E, Gentzler RD, Patel SB, Baranda J, Fang B, Squillante CM, Simonelli M, Werneke S, Curran D, Aix SP. Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study. Journal of Clinical Oncology. 38: 9610-9610. DOI: 10.1200/Jco.2020.38.15_Suppl.9610 |
0.493 |
|
| 2020 |
Piper-Vallillo A, Rotow JK, Aredo JV, Shaverdashvili K, Luo J, Carlisle JW, Husain H, Muzikansky A, Heist RS, Rangachari D, Ramalingam SS, Wakelee HA, Yu HA, Sequist LV, Bauml J, ... Neal JW, et al. High-dose osimertinib for CNS progression in EGFR+ non-small cell lung cancer (NSCLC): A multi-institutional experience. Journal of Clinical Oncology. 38: 9586-9586. DOI: 10.1200/Jco.2020.38.15_Suppl.9586 |
0.447 |
|
| 2020 |
Horn L, Lin HM, Padda SK, Aggarwal C, McCoach CE, Zhu Y, Yin Y, Lin J, Li S, Feng Z, Neal JW. Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions. Journal of Clinical Oncology. 38: 9580-9580. DOI: 10.1200/Jco.2020.38.15_Suppl.9580 |
0.489 |
|
| 2020 |
Ji J, Aredo JV, Piper-Vallillo A, Huppert L, Rotow JK, Husain H, Stewart SL, Cobb R, Wakelee HA, Blakely CM, Wong ML, Gubens MA, Chen J, Oxnard GR, McCoach CE, ... ... Neal JW, et al. Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study. Journal of Clinical Oncology. 38: 9570-9570. DOI: 10.1200/Jco.2020.38.15_Suppl.9570 |
0.507 |
|
| 2020 |
Moding EJ, Esfahani MS, Nabet B, Liu Y, Chabon JJ, He J, Qiao Y, Xu T, Yao L, Gandhi S, Liao ZX, Das M, Ramchandran K, Padda SK, Neal JW, et al. A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction. Journal of Clinical Oncology. 38: 9046-9046. DOI: 10.1200/Jco.2020.38.15_Suppl.9046 |
0.429 |
|
| 2020 |
Binkley MS, Jeon Y, Nesselbush M, Moding EJ, Nabet B, Almanza DS, Yoo C, Kurtz DM, Owen SG, Backhus LM, Berry MF, Shrager JB, Ramchandran K, Padda SK, Das M, ... Neal JW, et al. KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer. Journal of Clinical Oncology. 38: 9012-9012. DOI: 10.1200/Jco.2020.38.15_Suppl.9012 |
0.423 |
|
| 2020 |
Tseng D, Chiou S, Yang X, Reuben A, Wilhelmy J, McSween A, Conley S, Sinha R, Nabet B, Wang C, Shrager JB, Berry MF, Backhus LM, Lui N, Wakelee HA, ... Neal JW, et al. Discovery of a novel shared tumor antigen in human lung cancer. Journal of Clinical Oncology. 38: 3087-3087. DOI: 10.1200/Jco.2020.38.15_Suppl.3087 |
0.405 |
|
| 2020 |
Nabet BY, Esfahani MS, Hamilton EG, Chabon JJ, Moding EJ, Rizvi H, Steen CB, Chaudhuri AA, Liu CL, Hui AB, Stehr H, Goljenola L, Jin MC, Jeon Y, Tseng D, ... ... Neal JW, et al. Abstract 5666: A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer Tumor Biology. DOI: 10.1158/1538-7445.Am2020-5666 |
0.405 |
|
| 2020 |
Moding EJ, Liu Y, Nabet BY, Chabon JJ, Chaudhuri AA, Hui AB, Bonilla RF, Ko RB, Yoo CH, Gojenola L, Jones CD, He J, Qiao Y, Xu T, Heymach JV, ... ... Neal JW, et al. Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer Nature Cancer. 1: 176-183. DOI: 10.1038/s43018-019-0011-0 |
0.346 |
|
| 2020 |
Mazieres J, Tomasini P, Lusque A, Boucekine M, Gautschi O, Cortot A, Couraud S, Thai A, Ng T, Greillier L, Veillon R, Neal J, Popat S, Gounant V, Mhanna L, et al. 1279P Impact of KRAS mutations and subtypes on efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) Annals of Oncology. 31: S826-S827. DOI: 10.1016/j.annonc.2020.08.1593 |
0.399 |
|
| 2019 |
Hellyer JA, Gubens MA, Cunanan KM, Padda SK, Burns M, Spittler AJ, Riess JW, San Pedro-Salcedo M, Ramchandran KJ, Neal JW, Wakelee HA, Loehrer PJ. Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies. Lung Cancer (Amsterdam, Netherlands). 137: 71-75. PMID 31557562 DOI: 10.1016/J.Lungcan.2019.09.015 |
0.303 |
|
| 2019 |
Jeong Y, Hellyer JA, Stehr H, Hoang NT, Niu X, Das M, Padda SK, Ramchandran K, Neal JW, Wakelee HA, Diehn M. Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of non-small cell lung cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31548347 DOI: 10.1158/1078-0432.Ccr-19-1237 |
0.488 |
|
| 2019 |
Aredo JV, Padda SK, Kunder CA, Han SS, Neal JW, Shrager JB, Wakelee HA. Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes". Lung Cancer (Amsterdam, Netherlands). PMID 31492438 DOI: 10.1016/J.Lungcan.2019.08.020 |
0.44 |
|
| 2019 |
Hellyer JA, Stehr H, Das M, Padda SK, Ramchandran K, Neal JW, Diehn M, Wakelee HA. Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 134: 42-45. PMID 31319993 DOI: 10.1016/J.Lungcan.2019.05.002 |
0.502 |
|
| 2019 |
Aredo JV, Padda SK, Kunder CA, Han SS, Neal JW, Shrager JB, Wakelee HA. Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes. Lung Cancer (Amsterdam, Netherlands). 133: 144-150. PMID 31200821 DOI: 10.1016/J.Lungcan.2019.05.015 |
0.424 |
|
| 2019 |
Mazières J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van Den Heuvel M, Neal J, Peled N, Früh M, Ng TL, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 31125062 DOI: 10.1093/Annonc/Mdz167 |
0.477 |
|
| 2019 |
Sun TY, Sung AW, Neal JW. Steroid-Sparing Therapy for Tyrosine Kinase Inhibitor-Induced Pneumonitis. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 14: e75-e77. PMID 30922583 DOI: 10.1016/J.Jtho.2018.11.030 |
0.305 |
|
| 2019 |
Wang SXY, Zhang BM, Wakelee HA, Koontz MZ, Pan M, Diehn M, Kunder CA, Neal JW. Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib. Anti-Cancer Drugs. PMID 30762593 DOI: 10.1097/Cad.0000000000000765 |
0.454 |
|
| 2019 |
Shah A, Padda SK, Neal JW. Clinical and molecular characteristics of responders versus non-responders to immune checkpoint inhibitors (ICI) in NSCLC. Journal of Clinical Oncology. 37: 114-114. DOI: 10.1200/Jco.2019.37.8_Suppl.114 |
0.353 |
|
| 2019 |
Generalova O, Roy M, Hall ET, Velazquez B, Shah S, Fardeen T, Cunanan K, San Pedro-Salcedo M, Wakelee HA, Neal JW, Padda SK, Das M, Fan AC, Srinivas S, Fisher GA, et al. Feasibility and design of a cloud-based digital platform in patients with advanced cancer. Journal of Clinical Oncology. 37: 211-211. DOI: 10.1200/Jco.2019.37.27_Suppl.211 |
0.325 |
|
| 2019 |
Neal JW, Hausrath D, Wakelee HA, Cunanan K, Liu SV, Banwait M, Sequist LV, Stirling K, Piotrowska Z. Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis. Journal of Clinical Oncology. 37: 9083-9083. DOI: 10.1200/Jco.2019.37.15_Suppl.9083 |
0.434 |
|
| 2019 |
Janne PA, Neal JW, Camidge DR, Spira AI, Piotrowska Z, Horn L, Costa DB, Tsao AS, Patel JD, Gadgeel SM, Bazhenova L, Zhu VW, West H, Vincent S, Zhu J, et al. Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions. Journal of Clinical Oncology. 37: 9007-9007. DOI: 10.1200/Jco.2019.37.15_Suppl.9007 |
0.386 |
|
| 2019 |
Chaft JE, Costa DB, Muzikansky A, Shrager JB, Lanuti M, Huang J, Ramchandran K, Rangachari D, Huberman M, Piotrowska Z, Kris MG, Azzoli CG, Sequist LV, Neal JW. Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC. Journal of Clinical Oncology. 37: 8507-8507. DOI: 10.1200/Jco.2019.37.15_Suppl.8507 |
0.487 |
|
| 2019 |
Moding EJ, Liu Y, Nabet B, Chabon JJ, Chaudhuri A, Hui AB, He J, Qiao Y, Heymach J, Tsao AS, Liao ZX, Gomez DR, Ramchandran K, Neal JW, Wakelee HA, et al. ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer. Journal of Clinical Oncology. 37: 2547-2547. DOI: 10.1200/Jco.2019.37.15_Suppl.2547 |
0.343 |
|
| 2019 |
Liu X, Ao Z, Preiss JS, Neal J, Zhou LY, Sambucetti L, Wakelee HA. Abstract LB-238: Characterization of circulating tumor cells and its PD-L1 expression with high-sensitivity liquid biopsy panel in non-small cell lung cancer patients Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-238 |
0.408 |
|
| 2019 |
Reckamp KL, Akerley W, Edelman MJ, Halmos B, He K, Johnson M, Mudad R, Neal JW, Owonikoko TK, Patel JD, Patel SP, Riess JW, Sacher AG, Turcotte S, Villaruz LC, et al. Abstract CT225: A Phase Ib/IIa randomized pilot study to investigate the safety and tolerability of autologous T-cells with enhanced T-cell receptors specific to NY-ESO-1/LAGE-1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct225 |
0.469 |
|
| 2019 |
Jänne PA, Neal JW, Camidge DR, Spira A, Piotrowska Z, Horn L, Costa DB, Tsao A, Patel J, Gadgeel S, Bazhenova L, Zhu VW, West H, Vincent S, Zhu J, et al. Antitumor activity of TAK-788 in NSCLC With EGFR exon 20 insertions Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz338.077 |
0.368 |
|
| 2019 |
Reckamp KL, Akerley W, Calvo E, Clarke J, Edelman MJ, He K, Moreno V, Neal JW, Owonikoko TK, Patel JD, Patel SP, Riess JW, Sacher AG, Turcotte S, Villaruz LC, et al. Safety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz260.112 |
0.425 |
|
| 2019 |
Leal T, Wakelee H, Reckamp KL, Chiappori A, Oxnard GR, Waqar SN, Patel SP, Blumenschein GR, Neal JW, Harrow K, Holzhausen A, Selvaggi G, Zhou J, Horn L. PD2.04 Long Term Efficacy and Safety of Ensartinib in Pre-Treated Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients (eXalt2) Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.09.131 |
0.459 |
|
| 2019 |
Riely G, Neal J, Camidge D, Spira A, Piotrowska Z, Horn L, Costa D, Tsao A, Patel J, Gadgeel S, Bazhenova L, Zhu V, West H, Vincent S, Zhu J, et al. P1.01-127 Antitumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 in NSCLC with EGFR Exon 20 Insertions Journal of Thoracic Oncology. 14: S412-S413. DOI: 10.1016/J.Jtho.2019.08.842 |
0.415 |
|
| 2019 |
Lim F, Ponce S, Patel S, Herpen CV, Kurkjian C, Lou Y, Liu Y, Ramsingh G, Pal S, Neal J. P1.01-113 Phase 1b Trial of Cabozantinib or Cabozantinib Plus Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.828 |
0.478 |
|
| 2019 |
Skoulidis F, Arbour K, Hellmann M, Patil P, Marmarelis M, Owen D, Awad M, Murray J, Levy B, Hellyer J, Gainor J, Stewart T, Goldberg S, Dimou A, Bestvina C, ... ... Neal J, et al. MA11.11 STK11/LKB1 Genomic Alterations Are Associated with Inferior Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.591 |
0.32 |
|
| 2019 |
Wakelee H, Reckamp K, Leal T, Chiappori A, Waqar S, Zeman K, Neal J, Liang C, Harrow K, Holzhausen A, Zhou J, Selvaggi G, Horn L. P1.14-32 Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer Patients Treated with Ensartinib Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.1183 |
0.495 |
|
| 2019 |
Moding E, Nabet B, Liu Y, Chabon J, Chaudhuri A, Hui A, Binkley M, He J, Qiao Y, Xu T, Yao L, Gandhi S, Liao Z, Das M, Ramchandran K, ... ... Neal J, et al. Circulating Tumor DNA Changes During Chemoradiation for Lung Cancer Predict Patient Outcomes International Journal of Radiation Oncology*Biology*Physics. 105: S113. DOI: 10.1016/J.Ijrobp.2019.06.610 |
0.416 |
|
| 2018 |
Lam VK, Hong DS, Heymach JV, Blumenschein G, Butler MO, Johnson M, Creelan B, Gainor JF, Govindan R, Mudad R, Neal J, Brophy F, Fang F, Hyland N, Holdich T, et al. Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii731. PMID 32138012 DOI: 10.1093/Annonc/Mdy424.048 |
0.302 |
|
| 2018 |
Marcoux N, Gettinger SN, O'Kane G, Arbour KC, Neal JW, Husain H, Evans TL, Brahmer JR, Muzikansky A, Bonomi PD, Del Prete S, Wurtz A, Farago AF, Dias-Santagata D, Mino-Kenudson M, et al. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1801585. PMID 30550363 DOI: 10.1200/Jco.18.01585 |
0.507 |
|
| 2018 |
Pennell NA, Neal JW, Chaft JE, Azzoli CG, Jänne PA, Govindan R, Evans TL, Costa DB, Wakelee HA, Heist RS, Shapiro MA, Muzikansky A, Murthy S, Lanuti M, Rusch VW, et al. SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1800131. PMID 30444685 DOI: 10.1200/Jco.18.00131 |
0.518 |
|
| 2018 |
Myall NJ, Henry S, Wood D, Neal JW, Han SS, Padda SK, Wakelee HA. Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer. Clinical Lung Cancer. PMID 30442523 DOI: 10.1016/J.Cllc.2018.10.003 |
0.434 |
|
| 2018 |
Nguyen KH, Stehr H, Zhou L, Nguyen AH, Hiep PN, Van Cau N, Duy PC, Thorp R, Wakelee HA, Diehn M, Neal JW. Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam. Journal of Global Oncology. 1-9. PMID 30422746 DOI: 10.1200/Jgo.18.00086 |
0.483 |
|
| 2018 |
Sun TY, Niu X, Chakraborty A, Neal JW, Wakelee HA. Lengthy progression-free survival and intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-positive non-small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30217491 DOI: 10.1016/J.Jtho.2018.08.2030 |
0.473 |
|
| 2018 |
Xie L, Nagpal S, Wakelee HA, Li G, Soltys SG, Neal JW. Osimertinib for -Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study. The Oncologist. PMID 30126856 DOI: 10.1634/Theoncologist.2018-0264 |
0.486 |
|
| 2018 |
Wang SXY, Lei L, Guo HH, Shrager J, Kunder CA, Neal JW. Synchronous primary lung adenocarcinomas harboring distinct MET Exon 14 splice site mutations. Lung Cancer (Amsterdam, Netherlands). 122: 187-191. PMID 30032829 DOI: 10.1016/J.Lungcan.2018.06.019 |
0.435 |
|
| 2018 |
Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, Hellmann MD, Hirsch FR, Malik S, Neal JW, Papadimitrakopoulou VA, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). Journal For Immunotherapy of Cancer. 6: 75. PMID 30012210 DOI: 10.1186/S40425-018-0382-2 |
0.51 |
|
| 2018 |
Zweig JR, Neal JW. Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018788554. PMID 29939839 DOI: 10.1200/Jco.2018.78.8554 |
0.387 |
|
| 2018 |
Chin AL, Kumar KA, Guo HH, Maxim PG, Wakelee H, Neal JW, Diehn M, Loo BW, Gensheimer MF. Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer. Clinical Lung Cancer. PMID 29759331 DOI: 10.1016/J.Cllc.2018.04.003 |
0.446 |
|
| 2018 |
Horn L, Infante JR, Reckamp KL, Blumenshein GR, Leal TA, Waqar SN, Gitlitz BJ, Sanborn RE, Whisenant JG, Du L, Neal JW, Gockerman JP, Dukart G, Harrow K, Liang C, et al. Ensartinib (X-396) in ALK-positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29563138 DOI: 10.1158/1078-0432.Ccr-17-2398 |
0.461 |
|
| 2018 |
Gerber DE, Socinski MA, Neal JW, Wakelee HA, Shirai K, Sequist LV, Rosovsky RP, Lilenbaum RC, Bastos BR, Huang C, Johnson ML, Hesketh PJ, Subramaniam DS, Dietrich MF, Chai F, et al. Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 117: 44-49. PMID 29496255 DOI: 10.1016/J.Lungcan.2018.01.010 |
0.532 |
|
| 2018 |
Doebele RC, Riely GJ, Spira AI, Horn L, Piotrowska Z, Costa DB, Neal JW, Zhang S, Reichmann W, Kerstein D, Li S, Janne PA. First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non–small cell lung cancer (NSCLC). Journal of Clinical Oncology. 36: 9015-9015. DOI: 10.1200/Jco.2018.36.15_Suppl.9015 |
0.477 |
|
| 2018 |
Marcoux N, Gettinger SN, O'Kane GM, Arbour KC, Neal JW, Husain H, Evans TL, Brahmer JR, Muzikansky A, Bonomi P, Prete SAD, Wurtz A, Farago AF, Dias-Santagata D, Mino-Kenudson M, et al. Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC). Journal of Clinical Oncology. 36: 8573-8573. DOI: 10.1200/Jco.2018.36.15_Suppl.8573 |
0.48 |
|
| 2018 |
Salahudeen AA, Zhu J, Ju J, Giangarra V, Montesclaros L, Sapida J, Sharifi O, Lee J, Wagh D, Coller J, Neal JW, Padda SK, Wakelee HA, Sabatti C, Kuo CJ. Facile single cell profiling and clonotype analysis of NSCLC immune microenvironments. Journal of Clinical Oncology. 36: 12014-12014. DOI: 10.1200/Jco.2018.36.15_Suppl.12014 |
0.399 |
|
| 2018 |
Shukla ND, Salahudeen AA, Padda SK, Neal JW, Wakelee HA, Kuo CJ. Abstract B30: Three-dimensional organoid model for acquired drug resistance in non-small cell lung cancer Clinical Cancer Research. 24. DOI: 10.1158/1557-3265.Aacriaslc18-B30 |
0.462 |
|
| 2018 |
Salahudeen AA, Zhu J, Ju J, Batish A, Sutha K, Neal JT, Giangarra V, Montesclaros L, Sapida J, Sharifi O, Lee J, Zheng GX, Wagh DA, Coller JA, Neal JW, et al. Abstract 987: Organoid-based characterization of patient tumors and microenvironments at single cell resolution Cancer Research. 78: 987-987. DOI: 10.1158/1538-7445.Am2018-987 |
0.345 |
|
| 2018 |
Neal J, Doebele R, Riely G, Spira A, Horn L, Piotrowska Z, Costa D, Zhang S, Bottino D, Zhu J, Kerstein D, Li S, Jänne P. P1.13-44 Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.901 |
0.391 |
|
| 2018 |
Myall N, Henry S, Wood D, Neal J, Wakelee H. P1.01-71 Co-Mutations, Natural History, and Outcomes of BRAF-Mutated Non-Small Cell Lung Cancer at a Single Academic Cancer Center Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.627 |
0.447 |
|
| 2018 |
Leal T, Wakelee H, Reckamp K, Waqar S, Patel S, Blumenschein G, Neal J, Harrow K, Holzhausen A, Liang C, Dukart G, Horn L. PD.1.03 Ensartinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients: Updated Data Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.07.028 |
0.472 |
|
| 2018 |
Chaudhuri AA, Nabet BY, Merriott DJ, Jin M, Chen EL, Chabon JJ, Newman AM, Stehr H, Say C, Carter JN, Walters S, Becker H, Das M, Padda SK, Loo BW, ... ... Neal JW, et al. (OA02) Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer International Journal of Radiation Oncology*Biology*Physics. 101: e1-e2. DOI: 10.1016/J.Ijrobp.2018.02.041 |
0.46 |
|
| 2017 |
Padda SK, Terrone D, Tian L, Khuong A, Neal JW, Riess JW, Berry MF, Hoang CD, Burt BM, Leung AN, Schwartz EJ, Shrager JB, Wakelee HA. Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial Tumors. Journal of Thoracic Imaging. PMID 29219888 DOI: 10.1097/Rti.0000000000000310 |
0.308 |
|
| 2017 |
Vaca SD, Connolly ID, Ho C, Neal J, Hayden Gephart M. Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors. Neurosurgery. PMID 28945866 DOI: 10.1093/Neuros/Nyx429 |
0.5 |
|
| 2017 |
Zingone A, Brown D, Bowman ED, Vidal O, Sage J, Neal J, Ryan BM. Relationship between anti-depressant use and lung cancer survival. Cancer Treatment and Research Communications. 10: 33-39. PMID 28944316 DOI: 10.1016/J.Ctarc.2017.01.001 |
0.39 |
|
| 2017 |
Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, Khodadoust MS, Esfahani MS, Liu CL, Zhou L, Scherer F, Kurtz DM, Say C, Carter JN, Merriott DJ, ... ... Neal JW, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discovery. PMID 28899864 DOI: 10.1158/2159-8290.Cd-17-0716 |
0.479 |
|
| 2017 |
Gao RW, Berry MF, Kunder CA, Khuong AA, Wakelee H, Neal JW, Backhus LM, Shrager JB. Survival and risk factors for progression after resection of the dominant tumor in multifocal, lepidic-type pulmonary adenocarcinoma. The Journal of Thoracic and Cardiovascular Surgery. PMID 28863952 DOI: 10.1016/J.Jtcvs.2017.07.034 |
0.363 |
|
| 2017 |
Gensheimer MF, Hong JC, Chang-Halpenny C, Zhu H, Eclov NCW, To J, Murphy JD, Wakelee HA, Neal JW, Le QT, Hara WY, Quon A, Maxim PG, Graves EE, Olson MR, et al. Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 28830717 DOI: 10.1016/J.Radonc.2017.08.007 |
0.398 |
|
| 2017 |
Choi CYH, Wakelee HA, Neal JW, Pinder-Schenck MC, Yu HM, Chang SD, Adler JR, Modlin LA, Harsh GR, Soltys SG. Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial. International Journal of Radiation Oncology, Biology, Physics. 99: 16-21. PMID 28816142 DOI: 10.1016/J.Ijrobp.2017.04.041 |
0.439 |
|
| 2017 |
Mancuso MR, Neal JW. Novel systemic therapy against malignant pleural mesothelioma. Translational Lung Cancer Research. 6: 295-314. PMID 28713675 DOI: 10.21037/Tlcr.2017.06.01 |
0.321 |
|
| 2017 |
Chuang JC, Neal JW. The persistent promise of combining HGF/MET and EGFR inhibition in non-small cell lung cancer. Cancer. PMID 28472534 DOI: 10.1002/Cncr.30718 |
0.519 |
|
| 2017 |
Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, ... ... Neal JW, et al. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 35: 1403-1410. PMID 28447912 DOI: 10.1200/Jco.2016.70.9352 |
0.461 |
|
| 2017 |
Costa HA, Neal JW, Bustamante CD, Zehnder JL. Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer. Molecular Diagnosis & Therapy. PMID 28357677 DOI: 10.1007/S40291-017-0275-Y |
0.465 |
|
| 2017 |
Chuang JC, Stehr H, Liang Y, Das M, Huang J, Diehn M, Wakelee HA, Neal JW. ERBB2-mutated metastatic non-small cell lung cancer: response and resistance to targeted therapies. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 28167203 DOI: 10.1016/J.Jtho.2017.01.023 |
0.466 |
|
| 2017 |
Neal JW, Wakelee HA. Elusive Target of Angiogenesis in Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016716084. PMID 28165898 DOI: 10.1200/Jco.2016.71.6084 |
0.456 |
|
| 2017 |
Chaudhuri A, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, Carter JN, Merriott DJ, Liu CL, Kurtz DM, Dudley JC, Padda SK, Shrager JB, Neal JW, Wakelee HA, et al. Analysis of circulating tumor DNA in localized lung cancer for detection of molecular residual disease and personalization of adjuvant strategies. Journal of Clinical Oncology. 35: 8519-8519. DOI: 10.1200/Jco.2017.35.15_Suppl.8519 |
0.484 |
|
| 2017 |
Horn L, Reckamp KL, Patel S, Blumenschein G, Neal JW, Gitlitz B, Waqar S, Oxnard G, Brzezniak C, Dukart G, Tan F, Harrow K, Liang C, Gibbons J, Wakelee HA. Abstract CT151: CNS activity of ensartinib in ALK-positive non-small cell lung cancer patients Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct151 |
0.416 |
|
| 2017 |
Reckamp KL, Wakelee HA, Patel S, Blumenschein G, Neal JW, Gitlitz B, Waqar SN, Tan F, Harrow K, Horn L. 88OCNS activity of ensartinib in ALK+ non-small cell lung cancer (NSCLC) patients (pts) Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx091.008 |
0.502 |
|
| 2017 |
Chabon J, Chaudhuri A, Azad T, Kurtz D, Stehr H, Liu C, Martin JS, Merriott D, Carter J, Ayers K, Mansfield A, Jen J, Ren H, West R, Nair V, ... ... Neal J, et al. MA 13.01 Clinical and Pathological Variables Influencing Noninvasive Detection of Early Stage Lung Cancer Using Circulating Tumor DNA Journal of Thoracic Oncology. 12: S1851. DOI: 10.1016/J.Jtho.2017.09.560 |
0.401 |
|
| 2017 |
Wakelee H, Sanborn R, Nieva J, Waqar S, Brzezniak C, Bauman J, Neal J, Dukart G, Tan F, Harrow K, Liang C, Horn L. MA 07.02 Response to Ensartinib in TKI Naïve ALK+ NSCLC Patients Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.09.504 |
0.41 |
|
| 2017 |
Padda S, Reckamp K, Koczywas M, Neal J, Kawashima J, Kong S, Xin Y, Huang D, Wakelee H. P2.03-043 A Phase 1b Study of Erlotinib and Momelotinib for TKI-Naïve EGFR-Mutated Metastatic Non-Small Cell Lung Cancer Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.09.1294 |
0.495 |
|
| 2017 |
Chaudhuri A, Lovejoy A, Chabon J, Newman A, Stehr H, Say C, Carter J, Zhou L, West R, Shrager J, Neal J, Wakelee H, Loo B, Alizadeh A, Diehn M. MA17.07 Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Localized Lung Cancer Journal of Thoracic Oncology. 12: S445. DOI: 10.1016/J.Jtho.2016.11.520 |
0.397 |
|
| 2017 |
Gautschi O, Milia-Baron J, Filleron T, Wolf J, Carbone D, Owen D, Camidge DR, Narayanan V, Doebele R, Besse B, Remon J, Jänne P, Awad M, Peled N, Byoung C, ... ... Neal J, et al. MA16.03 Global RET Registry (GLORY): Activity of RET-Directed Targeted Therapies in RET-Rearranged Lung Cancers Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.508 |
0.43 |
|
| 2017 |
Wakelee H, Melnikova V, Karlovich C, Gadgeel S, Reckamp K, Goldman JW, Camidge DR, Pérol M, Ou S, Liu S, Yu H, Socinski M, Mekhail T, Solomon B, Natale R, ... ... Neal J, et al. MA08.01 A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.434 |
0.359 |
|
| 2017 |
Gadgeel S, Chen W, Piotrowska Z, Goldman JW, Wakelee H, Camidge DR, Varga A, Yu H, Papadimitrakopoulou V, Neal J, Soria J, Wozniak A, Riely G, Narayanan V, Mendenhall M, et al. P3.02b-115 Clinical Activity of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Previously Treated with Rociletinib Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.1783 |
0.511 |
|
| 2017 |
Doebele R, Horn L, Spira A, Piotrowska Z, Costa D, Neal J, Reichmann W, Kerstein D, Li S, Jänne P. P2.06-007 A Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non–Small Cell Lung Cancer (NSCLC) Journal of Thoracic Oncology. 12: S1072-S1073. DOI: 10.1016/J.Jtho.2016.11.1500 |
0.489 |
|
| 2017 |
Padda S, Reckamp K, Koczywas M, Neal J, Brachmann C, Kawashima J, Kong S, Xin Y, Huang D, Wakelee H. P2.06-004 A Phase 1b Study of Erlotinib and Momelotinib for EGFR TKI Naïve EGFR Mutated Metastatic Non-Small Cell Lung Cancer Journal of Thoracic Oncology. 12: S1070-S1071. DOI: 10.1016/J.Jtho.2016.11.1497 |
0.498 |
|
| 2017 |
Chaudhuri A, Chabon J, Lovejoy A, Newman A, Stehr H, Azad T, Carter J, Merriott D, Liu C, Kurtz D, Gensheimer M, Shrager J, Wakelee H, Neal J, Loo B, et al. Comparison of Circulating Tumor DNA Analysis and Surveillance Imaging After Treatment for Localized Lung Cancer International Journal of Radiation Oncology*Biology*Physics. 99: S114. DOI: 10.1016/J.Ijrobp.2017.06.269 |
0.404 |
|
| 2017 |
Xiang M, Gensheimer M, Maxim P, Wakelee H, Neal J, Diehn M, Loo B. Outcomes of Moderately Hypofractionated Intensity-Modulated Thoracic Radiotherapy with Concurrent Chemotherapy for Treatment of Non–Small Cell Lung Cancer International Journal of Radiation Oncology*Biology*Physics. 99: E504. DOI: 10.1016/J.Ijrobp.2017.06.1806 |
0.43 |
|
| 2017 |
Gensheimer MF, Hong JC, Chang-Halpenny CN, Eclov N, To J, Murphy JD, Wakelee HA, Neal JW, Le QT, Hara W, Quon A, Maxim PG, Graves EE, Olson MR, Diehn M, et al. Mid-radiation Therapy PET/CT for Prognostication and Detection of Early Progression in Patients With Stage III Non–small Cell Lung Cancer International Journal of Radiation Oncology Biology Physics. 99. DOI: 10.1016/J.Ijrobp.2017.06.1695 |
0.391 |
|
| 2017 |
Merriott D, Chaudhuri A, Jin M, Chabon J, Newman A, Stehr H, Say C, Carter J, Walters S, Becker H, Das M, Padda S, Loo B, Wakelee H, Neal J, et al. Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Lung Cancer International Journal of Radiation Oncology*Biology*Physics. 99: S20-S21. DOI: 10.1016/J.Ijrobp.2017.06.061 |
0.422 |
|
| 2017 |
Chaudhuri A, Lovejoy A, Chabon J, Newman A, Stehr H, Merriott D, Carter J, Azad T, Padda S, Gensheimer M, Wakelee H, Neal J, Loo B, Alizadeh A, Diehn M. Circulating Tumor DNA Analysis during Radiation Therapy for Localized Lung Cancer Predicts Treatment Outcome International Journal of Radiation Oncology*Biology*Physics. 99: S1-S2. DOI: 10.1016/J.Ijrobp.2017.06.021 |
0.395 |
|
| 2017 |
Wang S, Zhang B, Wakelee H, Diehn M, Kunder C, Neal J. Case Series of MET Exon 14 Skipping Mutation-positive Non–Small Cell Lung Cancers and Response to Crizotinib International Journal of Radiation Oncology*Biology*Physics. 98: 239. DOI: 10.1016/J.Ijrobp.2017.01.170 |
0.454 |
|
| 2016 |
Wang SX, Zhang BM, Wakelee H, Diehn M, Kunder CA, Neal JW. PS01.67: Case Series of MET Exon 14 Skipping Mutation-Positive Non-Small Cell Lung Cancers and Response to Crizotinib: Topic: Medical Oncology. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S312-S313. PMID 27969534 DOI: 10.1016/J.Jtho.2016.09.102 |
0.45 |
|
| 2016 |
Neal JW, Wakelee H, Padda SK, Bertrand S, Acevedo B, Holmes Tisch A, Pagtama JY, Soltys SG, Nagpal S. PS01.04: A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer: Topic: Medical Oncology. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S271-S272. PMID 27969472 DOI: 10.1016/J.Jtho.2016.09.040 |
0.402 |
|
| 2016 |
Horn L, Wakelee H, Reckamp KL, Blumenschein G, Infante JR, Carter CA, Waqar SN, Neal JW, Harrow K, Gockerman JP, Dukart G, Liang C, Gibbons JL, Hernandez J, Newman-Eerkes T, et al. MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC: Topic: Medical Oncology. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 11: S256-S257. PMID 27969449 DOI: 10.1016/J.Jtho.2016.09.017 |
0.314 |
|
| 2016 |
Park SM, Wong DJ, Ooi CC, Kurtz DM, Vermesh O, Aalipour A, Suh S, Pian KL, Chabon JJ, Lee SH, Jamali M, Say C, Carter JN, Lee LP, Kuschner WG, ... ... Neal JW, et al. Molecular profiling of single circulating tumor cells from lung cancer patients. Proceedings of the National Academy of Sciences of the United States of America. PMID 27956614 DOI: 10.1073/Pnas.1608461113 |
0.477 |
|
| 2016 |
Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Thomas Purcell W, Ross Camidge D, ... ... Neal JW, et al. Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nature Communications. 7: 13513. PMID 27841271 DOI: 10.1038/Ncomms13513 |
0.498 |
|
| 2016 |
Neal JW, Dahlberg SE, Wakelee HA, Aisner SC, Bowden M, Huang Y, Carbone DP, Gerstner GJ, Lerner RE, Rubin JL, Owonikoko TK, Stella PJ, Steen PD, Khalid AA, Ramalingam SS, et al. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. The Lancet. Oncology. PMID 27825638 DOI: 10.1016/S1470-2045(16)30561-7 |
0.535 |
|
| 2016 |
Chaudhuri AA, Lovejoy AF, Chabon JJ, Newman A, Stehr H, Say C, Aggarwal S, Carter JN, West RB, Neal JW, Wakelee HA, Loo BW, Alizadeh A, Diehn M. CAPP-Seq Circulating Tumor DNA Analysis for Early Detection of Tumor Progression After Definitive Radiation Therapy for Lung Cancer. International Journal of Radiation Oncology, Biology, Physics. 96: S41-S42. PMID 27675925 DOI: 10.1016/J.Ijrobp.2016.06.112 |
0.391 |
|
| 2016 |
Chuang JC, Shrager JB, Wakelee HA, Neal JW. Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy. Clinical Therapeutics. PMID 27368115 DOI: 10.1016/J.Clinthera.2016.06.005 |
0.435 |
|
| 2016 |
Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Purcell WT, Camidge DR, ... ... Neal JW, et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nature Communications. 7: 11815. PMID 27283993 DOI: 10.1038/Ncomms11815 |
0.468 |
|
| 2016 |
Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, Stehr H, Liu CL, Bratman SV, Say C, Zhou L, Carter JN, West RB, Sledge GW, Shrager JB, ... ... Neal JW, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnology. PMID 27018799 DOI: 10.1038/Nbt.3520 |
0.429 |
|
| 2016 |
Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, Stehr H, Liu CL, Bratman SV, Say C, Zhou L, Carter JN, West RB, Sledge GW, Shrager JB, ... ... Neal JW, et al. Integrated digital error suppression for noninvasive detection of circulating tumor DNA in NSCLC. Journal of Clinical Oncology. 34: e20500-e20500. DOI: 10.1200/Jco.2016.34.15_Suppl.E20500 |
0.324 |
|
| 2016 |
Horn L, Wakelee HA, Reckamp KL, Blumenschein GR, Infante JR, Carter CA, Waqar SN, Neal JW, Gockerman JP, Harrow K, Dukart G, Liang C, Gibbons JJ, Hernandez J, Newman-Eerkes T, et al. Plasma genotyping of patients enrolled on the expansion phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 34: 9056-9056. DOI: 10.1200/Jco.2016.34.15_Suppl.9056 |
0.467 |
|
| 2016 |
Wakelee HA, Gadgeel SM, Goldman JW, Reckamp KL, Karlovich CA, Melnikova V, Soria J, Yu HA, Solomon BJ, Perol M, Neal JW, Liu SV, Raponi M, Despain D, Erlander MG, et al. Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib. Journal of Clinical Oncology. 34: 9001-9001. DOI: 10.1200/Jco.2016.34.15_Suppl.9001 |
0.489 |
|
| 2016 |
Chabon JJ, Simmons A, Newman AM, Lovejoy AF, Esfahani MS, Haringsma H, Kurtz DM, Stehr H, Scherer F, Durkin KA, Otterson GA, Purcell WT, Camidge DR, Goldman JW, Sequist LV, ... ... Neal JW, et al. Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib. Journal of Clinical Oncology. 34: 9000-9000. DOI: 10.1200/Jco.2016.34.15_Suppl.9000 |
0.501 |
|
| 2016 |
Lovly CM, Infante JR, Blumenschein GR, Reckamp K, Wakelee H, Carter CA, Waqar SN, Neal J, Gockerman JP, Dukart G, Harrow K, Liang C, Gibbons JJ, Horn L. Abstract CT088: Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC) Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Ct088 |
0.407 |
|
| 2016 |
Piotrowska Z, Liu E, Varga A, Thakur M, Narayanan V, Liu SV, Neal J, Spiegel M, Solomon B, Yu H, Ou SI, Papadimitrakopoulou VA, Gadgeel S, Camidge DR, Soria J, et al. Rociletinib-associated cataracts in EGFR-mutant NSCLC Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw383.39 |
0.414 |
|
| 2016 |
Horn L, Wakelee H, Blumenschein G, Reckamp K, Waqar S, Carter C, Gitlitz B, Infante J, Sanborn R, Neal J, Gockerman J, Dukart G, Harrow K, Liang C, Gibbons J, et al. Phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx) Annals of Oncology. 27: vi419. DOI: 10.1093/Annonc/Mdw383.10 |
0.455 |
|
| 2016 |
Horn L, Wakelee H, Reckamp K, Blumenschein G, Infante J, Carter C, Waqar S, Neal J, Gockerman J, Harrow K, Dukart G, Liang C, Gibbons J, Hernandez J, Newman-Eerkes T, et al. P3.02a-001 Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK+ NSCLC: Topic: ALK Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.1631 |
0.307 |
|
| 2016 |
Neal JW, Wakelee H, Padda SK, Bertrand S, Acevedo B, Tisch AH, Pagtama JY, Soltys SG, Nagpal S. P2.03b-012 A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer Journal of Thoracic Oncology. 11. DOI: 10.1016/J.Jtho.2016.11.1293 |
0.404 |
|
| 2015 |
Myall NJ, Neal JW, Cho-Phan CD, Zhou LY, Stehr H, Zhou L, Diehn M, Wakelee HA. Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene. Clinical Lung Cancer. PMID 26776917 DOI: 10.1016/J.Cllc.2015.12.001 |
0.488 |
|
| 2015 |
Chuang JC, Neal JW. Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers. Translational Lung Cancer Research. 4: 639-641. PMID 26629437 DOI: 10.3978/J.Issn.2218-6751.2015.03.06 |
0.542 |
|
| 2015 |
Pugliese SB, Neal JW, Kwong BY. Management of Dermatologic Complications of Lung Cancer Therapies. Current Treatment Options in Oncology. 16: 50. PMID 26338208 DOI: 10.1007/S11864-015-0368-Y |
0.424 |
|
| 2015 |
Chuang JC, Neal JW, Niu XM, Wakelee HA. Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects. Lung Cancer (Amsterdam, Netherlands). 90: 1-7. PMID 26275476 DOI: 10.1016/J.Lungcan.2015.07.016 |
0.503 |
|
| 2015 |
Leung LS, Neal JW, Wakelee HA, Sequist LV, Marmor MF. Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy. American Journal of Ophthalmology. 160: 799-805.e1. PMID 26189086 DOI: 10.1016/J.Ajo.2015.07.012 |
0.31 |
|
| 2015 |
Das M, Padda SK, Frymoyer A, Zhou L, Riess JW, Neal JW, Wakelee HA. Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction. Lung Cancer (Amsterdam, Netherlands). 89: 280-6. PMID 26149476 DOI: 10.1016/J.Lungcan.2015.06.011 |
0.465 |
|
| 2015 |
Piotrowska Z, Niederst MJ, Karlovich CA, Wakelee HA, Neal JW, Mino-Kenudson M, Fulton L, Hata AN, Lockerman EL, Kalsy A, Digumarthy S, Muzikansky A, Raponi M, Garcia AR, Mulvey HE, et al. Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discovery. 5: 713-22. PMID 25934077 DOI: 10.1158/2159-8290.CD-15-0399 |
0.384 |
|
| 2015 |
Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R, Aisner DL, Doebele RC, Galasso C, Garon EB, Heist RS, ... ... Neal JW, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. The New England Journal of Medicine. 372: 1700-9. PMID 25923550 DOI: 10.1056/Nejmoa1413654 |
0.498 |
|
| 2015 |
Heist RS, Duda DG, Sahani DV, Ancukiewicz M, Fidias P, Sequist LV, Temel JS, Shaw AT, Pennell NA, Neal JW, Gandhi L, Lynch TJ, Engelman JA, Jain RK. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 112: 1547-52. PMID 25605928 DOI: 10.1073/Pnas.1424024112 |
0.405 |
|
| 2015 |
Neal JW, Gainor JF, Shaw AT. Developing biomarker-specific end points in lung cancer clinical trials. Nature Reviews. Clinical Oncology. 12: 135-46. PMID 25533947 DOI: 10.1038/Nrclinonc.2014.222 |
0.393 |
|
| 2015 |
Liang Y, Padda SK, Riess JW, West RB, Neal JW, Wakelee HA. Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. Lung Cancer (Amsterdam, Netherlands). 87: 34-8. PMID 25443273 DOI: 10.1016/J.Lungcan.2014.11.006 |
0.334 |
|
| 2015 |
Wakelee HA, Padda SK, Burns M, Spittler AJ, Riess JW, Pedro-Salcedo MS, Ramchandran KJ, Gubens MA, Neal JW, Sr PJL. Oral 1.01: Phase II trial of amrubicin in patients with previously treated advanced thymic malignancies Journal of Thoracic Disease. 7: 101. DOI: 10.3978/J.Issn.2072-1439.2015.Ab054 |
0.32 |
|
| 2015 |
Neal JW, Dahlberg SE, Wakelee HA, Aisner SC, Bowden M, Carbone DP, Ramalingam SS. Cabozantinib (C), erlotinib (E) or the combination (E+C) as second- or third-line therapy in patients with EGFR wild-type (wt) non-small cell lung cancer (NSCLC): A randomized phase 2 trial of the ECOG-ACRIN Cancer Research Group (E1512). Journal of Clinical Oncology. 33: 8003-8003. DOI: 10.1200/Jco.2015.33.15_Suppl.8003 |
0.376 |
|
| 2015 |
Wakelee HA, Padda SK, Burns M, Spittler AJ, Riess J, Pedro-Salcedo MS, Ramchandran K, Gubens MA, Neal JW, Loehrer PJ. Phase II trial of single agent amrubicin (A) in patients (pts) with previously treated advanced thymic malignancies (TM). Journal of Clinical Oncology. 33: 7580-7580. DOI: 10.1200/Jco.2015.33.15_Suppl.7580 |
0.312 |
|
| 2015 |
Zingone A, Brown D, Bowman E, Vidal O, Neal J, Sage J, Ryan BM. Abstract LB-182: Improved survival among lung cancer patients taking antidepressants Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-182 |
0.45 |
|
| 2015 |
Soria J-, Sequist LV, Goldman J, Wakelee HA, Neal J, Camidge R, Gadgeel S, Papadimitrakopoulou V, Dziadziuszko R, Piotrowska Z, Varga A, Solomon BJ. O10.3Rociletinib: an oral, irreversible, highly selective small molecule inhibitor of mutant EGFR including T790M Annals of Oncology. 26. DOI: 10.1093/Annonc/Mdv088.3 |
0.514 |
|
| 2015 |
Modlin LA, Choi CYH, Gibbs IC, Wakelee HA, Neal J, Pinder-Schenck MC, Chang SD, Adler JR, Harsh GR, Soltys SG. ePoster SessionVorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose-Escalation Trial International Journal of Radiation Oncology Biology Physics. 93. DOI: 10.1016/J.Ijrobp.2015.07.425 |
0.428 |
|
| 2014 |
Liang Y, Wakelee HA, Neal JW. Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non-Small-Cell Lung Cancer. Clinical Lung Cancer. PMID 25665893 DOI: 10.1016/J.Cllc.2014.12.009 |
0.471 |
|
| 2014 |
Nguyen KS, Neal JW, Wakelee H. Review of the current targeted therapies for non-small-cell lung cancer. World Journal of Clinical Oncology. 5: 576-87. PMID 25302162 DOI: 10.5306/Wjco.V5.I4.576 |
0.443 |
|
| 2014 |
Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, Liu CL, Neal JW, Wakelee HA, Merritt RE, Shrager JB, Loo BW, Alizadeh AA, Diehn M. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine. 20: 548-54. PMID 24705333 DOI: 10.1038/Nm.3519 |
0.443 |
|
| 2014 |
Riess JW, Nagpal S, Iv M, Zeineh M, Gubens MA, Ramchandran K, Neal JW, Wakelee HA. Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. Clinical Lung Cancer. 15: 202-6. PMID 24524822 DOI: 10.1016/J.Cllc.2013.12.009 |
0.498 |
|
| 2014 |
Riess JW, Bhattacharya N, Blenman KR, Neal JW, Hwang G, Pultar P, San-Pedro Salcedo M, Engleman E, Lee PP, Malik R, Wakelee HA. Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients. Immunopharmacology and Immunotoxicology. 36: 182-6. PMID 24494587 DOI: 10.3109/08923973.2013.864671 |
0.473 |
|
| 2014 |
Chen H, Modiano MR, Neal JW, Brahmer JR, Rigas JR, Jotte RM, Leighl NB, Riess JW, Kuo CJ, Liu L, Gao B, Dicioccio AT, Adjei AA, Wakelee HA. A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer British Journal of Cancer. 110: 602-608. PMID 24292447 DOI: 10.1038/Bjc.2013.735 |
0.46 |
|
| 2014 |
Earhart CM, Hughes CE, Gaster RS, Ooi CC, Wilson RJ, Zhou LY, Humke EW, Xu L, Wong DJ, Willingham SB, Schwartz EJ, Weissman IL, Jeffrey SS, Neal JW, Rohatgi R, et al. Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips. Lab On a Chip. 14: 78-88. PMID 23969419 DOI: 10.1039/C3Lc50580D |
0.325 |
|
| 2014 |
Neal JW, Wakelee HA, Feliciano JL, Goldberg SB, Morgensztern D, Das MS, Heist RS, Lennes IT, Muzikansky A, Edelman MJ, Gettinger SN, Sequist LV. A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 32: 8088-8088. DOI: 10.1200/Jco.2014.32.15_Suppl.8088 |
0.439 |
|
| 2014 |
Pennell NA, Neal JW, Chaft JE, Azzoli CG, Janne PA, Govindan R, Evans TL, Costa DB, Rosovsky RPG, Wakelee HA, Heist RS, Shaw AT, Temel JS, Shapiro MA, Muzikansky A, et al. SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC. Journal of Clinical Oncology. 32: 7514-7514. DOI: 10.1200/Jco.2014.32.15_Suppl.7514 |
0.441 |
|
| 2014 |
Jahchan NS, Dudley JT, Mazur PK, Flores N, Yang D, Palmerton A, Zmoos A, Vaka D, Tran KQt, Zhou M, Krasinska K, Riess JW, Neal JW, Khatri P, Park KS, et al. Abstract 4610: A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors Cancer Research. 74: 4610-4610. DOI: 10.1158/1538-7445.Am2014-4610 |
0.452 |
|
| 2014 |
Jahchan N, Joel D, Mazur P, Neal J, Khatri P, Butte A, Sage J. Abstract IA02: A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer. Clinical Cancer Research. 20: IA02-IA02. DOI: 10.1158/1078-0432.14AACRIASLC-IA02 |
0.33 |
|
| 2014 |
Diehn M, Bratman S, Newman A, Neal J, Wakelee H, Merritt R, Shrager J, Loo B, Alizadeh A. Ultrasensitive Detection of Circulating Tumor DNA in Non-Small Cell Lung Cancer by Deep Sequencing International Journal of Radiation Oncology*Biology*Physics. 90: S75. DOI: 10.1016/J.Ijrobp.2014.08.315 |
0.445 |
|
| 2014 |
Gerber DE, Socinski MA, Neal JW, Wakelee HA, Shirai K, Sequist LV, Rosovsky R, Lilenbaum R, Bastos BR, Huang C, Johnson ML, Hasketh PJ, Subramaniam DS, Chai F, Kazakin J, et al. Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) International Journal of Radiation Oncology Biology Physics. 90. DOI: 10.1016/J.Ijrobp.2014.08.213 |
0.408 |
|
| 2013 |
Neal JW, Sequist LV. Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond. Translational Lung Cancer Research. 2: 411-4. PMID 25806260 DOI: 10.3978/J.Issn.2218-6751.2013.10.06 |
0.486 |
|
| 2013 |
Jahchan NS, Dudley JT, Mazur PK, Flores N, Yang D, Palmerton A, Zmoos AF, Vaka D, Tran KQ, Zhou M, Krasinska K, Riess JW, Neal JW, Khatri P, Park KS, et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discovery. 3: 1364-77. PMID 24078773 DOI: 10.1158/2159-8290.Cd-13-0183 |
0.401 |
|
| 2013 |
Riess JW, Padda SK, Bangs CD, Das M, Neal JW, Adrouny AR, Cherry A, Wakelee HA. A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangements. Clinical Lung Cancer. 14: 592-5. PMID 23810364 DOI: 10.1016/J.Cllc.2013.04.008 |
0.506 |
|
| 2013 |
Riess JW, Nagpal S, Neal JW, Wakelee HA. A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib. Journal of the National Comprehensive Cancer Network : Jnccn. 11: 389-94. PMID 23584342 DOI: 10.6004/Jnccn.2013.0054 |
0.497 |
|
| 2013 |
Riess JW, Nagpal S, Das M, Neal JW, Kim JW, Wakelee HA. A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: e17-8. PMID 23328555 DOI: 10.1097/Jto.0B013E31827690Da |
0.364 |
|
| 2013 |
Neal JW, Wakelee HA. Aflibercept in lung cancer. Expert Opinion On Biological Therapy. 13: 115-20. PMID 23199019 DOI: 10.1517/14712598.2013.745847 |
0.354 |
|
| 2013 |
Bratman S, Newman A, To J, Wynne J, Neal J, Wakelee H, Shrager J, Loo B, Alizadeh A, Diehn M. Noninvasive and Ultrasensitive Quantitation of Circulating Tumor DNA by Hybrid Capture and Deep Sequencing International Journal of Radiation Oncology*Biology*Physics. 87: S92. DOI: 10.1200/Jco.2014.32.15_Suppl.11016 |
0.444 |
|
| 2013 |
Sequist LV, Soria J, Gadgeel SM, Wakelee HA, Camidge DR, Varga A, Fidias P, Wozniak AJ, Neal JW, Doebele RC, Garon EB, Jaw-Tsai SS, Stern JC, Allen AR, Goldman JW. First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M. Journal of Clinical Oncology. 31: 2524-2524. DOI: 10.1200/Jco.2013.31.15_Suppl.2524 |
0.424 |
|
| 2012 |
Padda S, Neal JW, Wakelee HA. MET inhibitors in combination with other therapies in non-small cell lung cancer. Translational Lung Cancer Research. 1: 238-53. PMID 25806189 DOI: 10.3978/J.Issn.2218-6751.2012.10.08 |
0.505 |
|
| 2012 |
Riess JW, Neal JW. Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: S385-6. PMID 23160327 DOI: 10.1097/Jto.0B013E31826Df166 |
0.479 |
|
| 2012 |
Nguyen KS, Neal JW. First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors. Biologics : Targets & Therapy. 6: 337-45. PMID 23055691 DOI: 10.2147/Btt.S26558 |
0.533 |
|
| 2012 |
Goldberg SB, Supko JG, Neal JW, Muzikansky A, Digumarthy S, Fidias P, Temel JS, Heist RS, Shaw AT, McCarthy PO, Lynch TJ, Sharma S, Settleman JE, Sequist LV. A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 1602-8. PMID 22878749 DOI: 10.1097/Jto.0B013E318262De4A |
0.498 |
|
| 2012 |
Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, Reck M. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2046-54. PMID 22547592 DOI: 10.1200/Jco.2011.38.4032 |
0.45 |
|
| 2012 |
Neal JW, Sequist LV. Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2280-2. PMID 22508823 DOI: 10.1200/Jco.2011.41.0860 |
0.511 |
|
| 2012 |
Chen H, Modiano MR, Neal JW, Brahmer JR, Rigas JR, Jotte RM, Leighl NB, Liu L, Lisano JM, Adjei AA, Wakelee HA. A phase II multicenter study of aflibercept (AFL) in combination with cisplatin (C) and pemetrexed (P) in patients with previously untreated advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 30: 7541-7541. DOI: 10.1200/Jco.2012.30.15_Suppl.7541 |
0.418 |
|
| 2012 |
Neal JW, Pennell NA, Govindan R, Lanuti M, Rosovsky RPG, Heist RS, Shaw AT, Temel JS, Muzikansky A, Janne PA, Lynch TJ, Azzoli CG, Sequist LV. The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 30: 7010-7010. DOI: 10.1200/Jco.2012.30.15_Suppl.7010 |
0.489 |
|
| 2012 |
Bratman S, Eclov N, Modlin L, Neal J, Loo B, Wu G, Richardson K, Newman A, Alizadeh A, Diehn M. Cell-free DNA as a Biomarker of Residual Disease Following Radiation Therapy for Non-small Cell Lung Cancer International Journal of Radiation Oncology*Biology*Physics. 84: S713. DOI: 10.1016/J.Ijrobp.2012.07.1908 |
0.436 |
|
| 2011 |
Pennell NA, Neal JW, Govindan R, Janne PA, Evans TL, Costa DB, Rosovsky RP, Lanuti M, Azzoli CG, Sequist LV. The SELECT trial: A multicenter phase II trial of adjuvant erlotinib (E) in patients with resected, early-stage non-small cell lung cancer (NSCLC) and confirmed mutations in the epidermal growth factor receptor (EGFR). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS209. PMID 28023496 DOI: 10.1200/Jco.2011.29.15_Suppl.Tps209 |
0.518 |
|
| 2011 |
Heist RS, Duda GD, Sahani D, Ancukiewicz M, Fidias P, Sequist LV, Shaw AT, Temel JS, Lennes IT, Neal JW, Pennell NA, Lynch TJ, Engelman JA, Jain RK. Phase II trial of carboplatin, abraxane, and bevacizumab in NSCLC. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e18016. PMID 28020106 DOI: 10.1200/Jco.2011.29.15_Suppl.E18016 |
0.368 |
|
| 2011 |
Neal JW, Gubens MA, Wakelee HA. Current management of small cell lung cancer. Clinics in Chest Medicine. 32: 853-63. PMID 22054891 DOI: 10.1016/J.Ccm.2011.07.002 |
0.444 |
|
| 2011 |
Riess JW, Neal JW. Targeting FGFR, ephrins, Mer, MET, and PDGFR-α in non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: S1797-8. PMID 22005534 DOI: 10.1097/01.Jto.0000407562.07029.52 |
0.442 |
|
| 2011 |
Mak RH, Doran E, Muzikansky A, Kang J, Neal JW, Baldini EH, Choi NC, Willers H, Jackman DM, Sequist LV. Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC. The Oncologist. 16: 886-95. PMID 21632451 DOI: 10.1634/Theoncologist.2011-0040 |
0.491 |
|
| 2011 |
Neal JW, Shaw AT. One allele's loss is another's gain: alterations of NKX2-8 in non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 638-9. PMID 21163872 DOI: 10.1158/1078-0432.Ccr-10-3081 |
0.407 |
|
| 2011 |
Neal JW, Gubens MA, Wakelee HA. Emerging treatments for small-cell lung cancer: Phase II and III trials Clinical Investigation. 1: 255-263. DOI: 10.4155/Cli.10.30 |
0.486 |
|
| 2010 |
Neal JW. The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer. Future Oncology (London, England). 6: 1827-32. PMID 21142856 DOI: 10.2217/Fon.10.156 |
0.475 |
|
| 2010 |
Neal JW, Heist RS, Fidias P, Temel JS, Huberman M, Marcoux JP, Muzikansky A, Lynch TJ, Sequist LV. Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 1855-8. PMID 20975380 DOI: 10.1097/Jto.0B013E3181F0Bee0 |
0.501 |
|
| 2010 |
Neal JW, Sequist LV. Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. Current Treatment Options in Oncology. 11: 36-44. PMID 20676809 DOI: 10.1007/S11864-010-0120-6 |
0.5 |
|
| 2010 |
Neal JW, Sequist LV. First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations. Clinical Advances in Hematology & Oncology : H&O. 8: 119-26. PMID 20386533 |
0.387 |
|
| 2010 |
Neal JW, Sequist LV. Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations. Nature Reviews. Clinical Oncology. 7: 71-2. PMID 20118973 DOI: 10.1038/Nrclinonc.2009.191 |
0.479 |
|
| 2010 |
Neal JW. Histology matters: individualizing treatment in non-small cell lung cancer. The Oncologist. 15: 3-5. PMID 20086166 DOI: 10.1634/Theoncologist.2009-0306 |
0.496 |
|
| 2010 |
Heist RS, Duda GD, Sahani D, Pennell NA, Neal JW, Ancukiewicz M, Engelman JA, Lynch TJ, Jain RK. In vivo assessment of the effects of bevacizumab in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 28: 7612-7612. DOI: 10.1200/Jco.2010.28.15_Suppl.7612 |
0.51 |
|
| 2010 |
Neal JW, Pennell NA, Goodgame BW, Lanuti M, Heist RS, Shaw AT, Temel JS, Janne PA, Azzoli CG, Sequist LV. A multicenter phase II trial of adjuvant erlotinib in patients with resected non-small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR): Toxicity evaluation. Journal of Clinical Oncology. 28: 7078-7078. DOI: 10.1200/Jco.2010.28.15_Suppl.7078 |
0.511 |
|
| 2010 |
Mak RH, Doran E, Muzikansky A, Neal JW, Baldini EH, Choi NC, Willers H, Jackman DM, Sequist LV. KRAS Mutation is Associated with Decreased Overall Survival after Thoracic Radiation Therapy in Patients with Locally Advanced Non-small Cell Lung Cancer International Journal of Radiation Oncology Biology Physics. 78. DOI: 10.1016/J.Ijrobp.2010.07.121 |
0.473 |
|
| 2003 |
Barry SM, Zisoulis DG, Neal JW, Clipstone NA, Kansas GS. Induction of FucT-VII by the Ras/MAP kinase cascade in Jurkat T cells. Blood. 102: 1771-8. PMID 12738675 DOI: 10.1182/Blood-2002-11-3551 |
0.683 |
|
| 2003 |
Neal JW, Clipstone NA. A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts. The Journal of Biological Chemistry. 278: 17246-54. PMID 12598522 DOI: 10.1074/Jbc.M300528200 |
0.7 |
|
| 2002 |
Neal JW, Clipstone NA. Calcineurin mediates the calcium-dependent inhibition of adipocyte differentiation in 3T3-L1 cells. The Journal of Biological Chemistry. 277: 49776-81. PMID 12351639 DOI: 10.1074/Jbc.M207913200 |
0.686 |
|
| 2001 |
Neal JW, Clipstone NA. Glycogen synthase kinase-3 inhibits the DNA binding activity of NFATc. The Journal of Biological Chemistry. 276: 3666-73. PMID 11063740 DOI: 10.1074/Jbc.M004888200 |
0.681 |
|
| Show low-probability matches. |